Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04770272
Recruitment Status : Recruiting
First Posted : February 25, 2021
Last Update Posted : January 13, 2022
Sponsor:
Collaborators:
Roche Pharma AG
Phaon Scientific GmbH
University Hospital, Essen
University Hospital Erlangen
Information provided by (Responsible Party):
Palleos Healthcare GmbH

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week window to chemotherapy with PDL1-inhibition (Atezolizumab) and identify biomarkers predicting (early) response to or resistance against Atezolizumab (alone and with CTX) allowing patients stratification in future clinical trials

Condition or disease Intervention/treatment Phase
Triple-negative Breast Cancer Drug: Atezolizumab 840 MG in 14 ML Injection Drug: Atezolizumab 1200 MG in 20 ML Injection Drug: Carboplatin Drug: Paclitaxel Drug: Epirubicin Drug: Cyclophosphamide Procedure: Biopsy Arm A Procedure: Biopsy Arm B Procedure: Surgery Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 458 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)
Actual Study Start Date : March 1, 2021
Estimated Primary Completion Date : August 1, 2023
Estimated Study Completion Date : January 1, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A
2 weeks Atezolizumab monotherapy before biopsy, followed by a 12-week therapy with Paclitaxel + Carboplatin+ Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
 Drug: Atezolizumab 840 MG in 14 ML Injection
840 mg Day 1 for two weeks
Other Name: Tecentriq

Drug: Atezolizumab 1200 MG in 20 ML Injection
1200 mg Day 1 every 3 weeks for 8 cycles
Other Name: Tecentriq

Drug: Carboplatin
Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles

Drug: Paclitaxel
Paclitaxel 80 mg/m² IV weekly x 12 cycles

Drug: Epirubicin
90 mg/m2, day 1 for 4 cycles (12 weeks)

Drug: Cyclophosphamide
600 mg/m2, day 1 for 4 cycles (12 weeks)

Procedure: Biopsy Arm A
1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.

Procedure: Surgery
After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
Active Comparator: Arm B
12-week therapy with Paclitaxel + Carboplatin + Atezolizumab every 3 weeks for 4 cycles. This will be followed by Epirubicin + Cyclophosphamide + Atezolizumab every 3 weeks for 4 cycles.
 Drug: Atezolizumab 1200 MG in 20 ML Injection
1200 mg Day 1 every 3 weeks for 8 cycles
Other Name: Tecentriq

Drug: Carboplatin
Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles

Drug: Paclitaxel
Paclitaxel 80 mg/m² IV weekly x 12 cycles

Drug: Epirubicin
90 mg/m2, day 1 for 4 cycles (12 weeks)

Drug: Cyclophosphamide
600 mg/m2, day 1 for 4 cycles (12 weeks)

Procedure: Biopsy Arm B
1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.

Procedure: Surgery
After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Pathological complete response (ypT0/is, ypN0) [ Time Frame: after 29-30 weeks in Arm A and after 27-28 weeks in Arm B. ]
    Pathological Complete Response defined as no residual invasive tumor cells in the breast and in the lymph nodes (ypT0/is, ypN0)


Secondary Outcome Measures :
  1. Safety Measures [ Time Frame: from date of randomization up to 59 months ]
    Safety (incidence, relationship, seriousness, and severity of all AEs, SAEs, AESIs coded by medical dictionary for regulatory activities (MedDRA), summarized by Preferred Term and System Organ Class and graded according to common terminology criteria of adverse events (CTCAE V5.0)

  2. Pathological Complete Response (ypT0/is, ypN0) (ER/PR expression of <1%) [ Time Frame: after 29-30 weeks in Arm A and after 27-28 weeks in Arm B ]
    Pathological complete response defined as no residual invasive tumor cells in the breast and in the lymph nodes (ypT0/is, ypN0) in patients with an ER/PR expression of <1% and an ER/PR expression of 1% to 10%.

  3. Pathological Complete Response (ypT0, ypN0) [ Time Frame: after 29-30 weeks in Arm A and after 27-28 weeks in Arm B. ]
    Pathological complete response defined as no tumor cells (invasive and no non-invasive) in the breast but also in the lymph nodes (ypN0, ypT0)

  4. Near Pathological Complete Response (Near pCR) [ Time Frame: after 29-30 weeks in Arm A and after 27-28 weeks in Arm B. ]
    Near pCR defined as residual tumor <5 mm in the breast irrespective of in situ and lymph nodes status

  5. Pathological Complete Response (no invasive tumor) [ Time Frame: after 29-30 weeks in Arm A and after 27-28 weeks in Arm B. ]
    Pathological Complete Response defined as no invasive tumor in the breast, irrespective of lymph node status

  6. Decrease of Ki-67 expression as continuous predictor [ Time Frame: after 14/28 days (+/- 2 days) of treatment ]
    Decrease of Ki-67 expression versus baseline after 14/28 days (+/- 2 days) of treatment as continuous predictor

  7. Tumor-infiltrating lymphocytes (TILs) [ Time Frame: after 14/28 days (+/- 2 days) of treatment ]
    TILs after 14/28 days (+/- 2 days) of treatment as continuous predictor

  8. Complete Cell Cycle Arrest (CCCA) [ Time Frame: after 14/28 days (+/- 2 days) of treatment ]
    CCCA: Ki-67 expression ≤ 2.7% after 14/28 days (+/- 2 days) of treatment

  9. Low cellularity [ Time Frame: after 14/28 days (+/- 2 days) of treatment ]
    Low cellularity: < 500 tumor cells after 14/28 days (+/- 2 days) of treatment

  10. Decrease of Ki-67 expression [ Time Frame: after 14/28 days (+/- 2 days) of treatment ]
    Decrease of Ki-67 expression versus baseline by 30% or more after 14/28 days (+/- 2 days) of treatment

  11. Tumor-infiltrating lymphocytes (TILs) ≥ 60% [ Time Frame: after 14/28 days (+/- 2 days) of treatment ]
    TILs ≥ 60% after 14/28 days (+/- 2 days) of treatment

  12. Combined early response [ Time Frame: after 14/28 days (+/- 2 days) of treatment ]

    Combined early response defined by

    • CCCA (Ki-67 expression < 2.7%) or
    • low cellularity or
    • decrease of Ki-67 expression (versus baseline) by 30% or more or
    • TILs ≥ 60%

  13. Disease free survival (DFS) [ Time Frame: from randomization up to 59 months until date of occurrence of no disease to the first occurrence of disease recurrence or death from any cause ]
    Disease free survival (DFS) defined as time from the first date of no disease [i.e. date of surgery] to the first occurrence of disease recurrence or death from any cause

  14. Overall survival (OS) [ Time Frame: from randomization up to 59 months until date of death from any cause ]
    Overall survival (OS) defined as length of time from randomization to death from any cause

  15. Event free survival (EFS) [ Time Frame: from randomization up to 59 months until date of death from any cause, failure to achieve remission after induction therapy, relapse in any site, or second malignancy ]
    Event free survival (EFS) defined as length of time after randomization till death from any cause, failure to achieve remission after induction therapy, relapse in any site, or second malignancy


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female and male patients, age at diagnosis 18 years and above
  • Written informed consent prior to admission to this study
  • Histologically confirmed unilateral primary invasive carcinoma of the breast
  • Clinical T1c - T4d
  • Stage N0-N3 until 21 patients (5%) with stage N3 are randomized, thereafter N0-N2

  • Triple negative breast cancer defined by and confirmed by central pathology:

    • ER negative (<10% positive cells in IHC) and PR negative (<10% positive cells on IHC)

    • HER2 negative breast cancer:

      • Either defined by IHC: ICH scores of 0-1 or an ICH score of 2 in combination with a negative in-situ-hybridization (ISH)
      • Or defined by ISH: negative ISH
  • Identifiable PD-L1 IC-status by central pathology (positive or negative) by means of VENTANA PD-L1 (SP142) assay; positive status is defined by PD-L1 expression on IC on ≥ 1% of the tumor area, negative status is defined by PD-L1 expression on IC on < 1% of the tumor area
  • No clinical evidence for distant metastasis (cM0)
  • Tumor block available for translational research
  • Performance Status Eastern Cooperative Oncology Group (ECOG) ≤ 1 or KI ≥ 80 %
  • Negative pregnancy test (urine or serum) within 7 days prior to screening in premenopausal patients

  • Women of childbearing potential and male patients with partners of childbearing potential must accept to implement a highly effective (less than 1% failure rate according to Pearl index) including at least one non-hormonal contraceptive measures during the study treatment and for 5 months following the last dose of study treatment such as:

    • Intrauterine device (IUD)
    • bilateral tubal occlusion
    • vasectomized partner
    • sexual abstinence
  • The patient must be accessible for treatment and follow-up

  • Normal cardiac function:

    • Normal electrocardiogram (ECG) (within 6 weeks prior to screening)
    • Normal left ventricular ejection fraction (LVEF) on echocardiorgaphy

  • Normal thyroid function

    o Normal TSH and FT4

  • Blood counts within 14 days prior screening:

    • absolute neutrophile count (ANC) must be ≥ 1,500/mm3
    • Platelet count must be ≥ 100,000 / mm3
    • Hemoglobin must be ≥ 10 g/dl

  • Hepatic functions:

    • Total bilirubin must be ≤ 1 upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation > 1 x ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin
    • Alkaline phosphatase must be ≤ 2.5 x ULN for the lab
    • AST and ALT must be ≤1.5 x ULN for the lab.
    • Patients with AST and ALT or alkaline phosphatase > 1 x ULN are eligible for inclusion if liver imaging (computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET-CT, or PET scan) performed within 3 months prior to randomization (and part of standard of care) does not demonstrate metastatic disease and the requirements in criterion (just above) are met
    • Patients with alkaline phosphatase that is > 1 x ULN but less than or equal to 2.5 x ULN or with unexplained bone pain are eligible if bone imaging does not demonstrate metastatic disease.
    • Creatinine clearance ≥ 40 ml/min performed 28 days prior to screening

Exclusion Criteria:

  • Previous history of malign diseases, non-melanoma skin cancer and carcinoma of the cervix are allowed if treated with curative intent
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of Paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide or Atezolizumab
  • Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol
  • Concurrent treatment with other drugs that are contraindicating the use of the study drugs
  • Existing pregnancy
  • Breastfeeding
  • Sequential breast cancer
  • Concurrent treatment with other experimental drugs and participation in another clinical trial or clinical research project (except registry study) within 30 days prior to study entry

  • Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including but not confined to:

    • Uncompensated chronic heart failure or systolic dysfunction (LVEF < 55%, congestive heart failure (CHF) New York Heart Association (NYHA) classes II-IV),
    • unstable arrhythmias requiring treatment i.e., atrial tachycardia with a heart rate ≥ 100/bpm at rest, significant ventricular arrhythmia (ventricular tachycardia) or highergrade AV-block,
    • Angina pectoris within the last 6 months requiring anti-anginal medication,
    • Clinically significant valvular heart disease,
    • Evidence of myocardial infarction on electrocardiogram (ECG),
    • Poorly controlled hypertension (e.g., systolic > 180 mmHg or diastolic > 100 mmHg).

  • Inadequate organ function including but not confined to:

    • hepatic impairment as defined by bilirubin > 1.5 x ULN
    • pulmonary disease (severe dyspnea at rest requiring oxygen therapy)

  • Abnormal blood values:

    • Platelet count below 100,000/mm3
    • AST/ALT > 1.5 x ULN
    • Hypokalaemia > CTCAE grade 1
    • Neutropenia > CTCAE grade 1
    • Anaemia > CTCAE grade 1
  • Administration of a live, attenuated vaccine within 4 weeks before cycle 1 day 1 or anticipation that such a vaccine will be required during the study
  • Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-2) within 28 days or 5 half-lives of the drug, whichever is longer, prior to randomization.
  • Treatment with systemic immunosuppressive medications (including but not limited to Prednisone, Cyclophosphamide, Azathioprine, Methotrexate, Thalidomide, and anti-tumor necrosis [anti-TNF] factor agents) within 14 days prior to screening or anticipation of need for systemic immunosuppressive medications during the study
  • Patients with prior allogeneic stem cell or solid organ transplantation

  • Active or history of autoimmune disease or immune deficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.
    • Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are permitted provided all of following conditions are met: Rash must cover < 10% of body surface area; Disease is well controlled at baseline and requires only low-potency topical corticosteroids; No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, Methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral Corticosteroids within the previous 12 months.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • History of HIV infection, hepatitis B or hepatitis C infection.
  • Patients with significant cardiovascular disease
  • Patients with inadequate hematological and end-organ function
  • Patients receiving therapeutic anti-coagulants
  • Stage N3, as soon as 21 patients with stage N3 are randomized
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04770272


Contacts
Layout table for location contacts
Contact: Palleos Healthcare GmbH 004961195019 ext 0 info@palleos.com

Locations
Layout table for location information
Germany
Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe; Recruiting
Bottrop, Germany, 46236
Sponsors and Collaborators
Palleos Healthcare GmbH
Roche Pharma AG
Phaon Scientific GmbH
University Hospital, Essen
University Hospital Erlangen
Investigators
Layout table for investigator information
Study Director: Iris Reiser, Dr. Palleos Healthcare GmbH
Principal Investigator: Hans-Christian Kolberg, PD Dr. Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe; 46236 Bottrop
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:
Gelman A, Stern HS, Carlin JB, Dunson DB, Vehtari A & Rubin DB. Bayesian data analysis. Chapman and Hall/CRC. 2013
Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C & Thill M (2019, Dezember 12). Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer. SABCS 2019, Marc.
Ibrahim JG, Chen MH & Sinha, D. (2014). Bayesian Survival Analysis. In N. Balakrishnan, T. Colton, B. Everitt, W. Piegorsch, F. Ruggeri, & J. L. Teugels (Hrsg.), Wiley StatsRef: Statistics Reference Online (S. stat06003). John Wiley & Sons
Klein JP & Moeschberger ML (2010). Survival analysis: Techniques for censored and truncated data (2. ed., corr. 3. print). Springer.
Liedtke C, Feuerhake F, Garke M, Christgen M, Kates RE, Grischke EM, Forstbauer H, Braun MW, Warm MR & Hackmann C (2018). Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial. American Society of Clinical Oncology.
Loi S, Schmid P, Aktan G, Karantza V & Salgado R (2019). 4O Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+ chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial. Annals of Oncology
Loibl S, Werutsky G, Nekljudova V, Seiler S, Blohmer JU, Denkert C, Hanusch C, Huober JB, Jackisch C, Kummel S, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Von Minckwitz G & Furlanetto J (2017). Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer: A pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials. Journal of Clinical Oncology
Royston P & Sauerbrei W (2008). Multivariable Model-Building. John Wiley & Sons, Ltd.
Schmid P, Cortés J, Dent R, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C, Park YH & Hui R (2019). KEYNOTE-522: Phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Annals of Oncology
Tibshirani R (1996). Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society. Series B (Methodological)

Layout table for additonal information
Responsible Party: Palleos Healthcare GmbH
ClinicalTrials.gov Identifier: NCT04770272    
Other Study ID Numbers: Phaon1
First Posted: February 25, 2021    Key Record Dates
Last Update Posted: January 13, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Palleos Healthcare GmbH:
TNBC
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Cyclophosphamide
Carboplatin
Atezolizumab
Epirubicin
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
 Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors